This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout

References
Cook LB, Fuji S, Hermine O, Bazarbachi A, Ramos JC, Ratner L, et al. Revised adult t-cell leukemia-lymphoma international consensus meeting report. J Clin Oncol. 2019;37:677–87. https://doi.org/10.1200/jco.18.00501. e-pub ahead of print 2019/01/19
Kanda J, Hishizawa M, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y, et al. Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study. Blood. 2012;119:2141–8. https://doi.org/10.1182/blood-2011-07-368233. e-pub ahead of print 2012/01/12
Ishida T, Hishizawa M, Kato K, Tanosaki R, Fukuda T, Taniguchi S, et al. Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. Blood. 2012;120:1734–41. https://doi.org/10.1182/blood-2012-03-414490. e-pub ahead of print 2012/06/13
Fan J, Ma G, Nosaka K, Tanabe J, Satou Y, Koito A, et al. APOBEC3G generates nonsense mutations in human T-cell leukemia virus type 1 proviral genomes in vivo. J Virol. 2010;84:7278–87. https://doi.org/10.1128/jvi.02239-09. e-pub ahead of print 2010/05/14
Kannagi M, Hasegawa A, Takamori A, Kinpara S, Utsunomiya A. The roles of acquired and innate immunity in human T-cell leukemia virus type 1-mediated diseases. Front Microbiol. 2012;3:323. https://doi.org/10.3389/fmicb.2012.00323. e-pub ahead of print 2012/09/13
Jacobson S, Shida H, McFarlin DE, Fauci AS, Koenig S. Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature. 1990;348:245–8. https://doi.org/10.1038/348245a0. e-pub ahead of print 1990/11/15
Bazarbachi A, Cwynarski K, Boumendil A, Finel H, Fields P, Raj K, et al. Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: a retrospective study by the EBMT LWP. Bone Marrow Transpl. 2014;49:1266–8. https://doi.org/10.1038/bmt.2014.143. e-pub ahead of print 2014/07/17
Shah NN, Waldmann TA. GVL for ATL? Blood. 2013;121:6–7. https://doi.org/10.1182/blood-2012-11-464628. e-pub ahead of print 2013/01/05
Tamiya S, Matsuoka M, Etoh K, Watanabe T, Kamihira S, Yamaguchi K, et al. Two types of defective human T-lymphotropic virus type I provirus in adult T-cell leukemia. Blood. 1996;88:3065–73. e-pub ahead of print 1996/10/15
Miyazaki M, Yasunaga J, Taniguchi Y, Tamiya S, Nakahata T, Matsuoka M. Preferential selection of human T-cell leukemia virus type 1 provirus lacking the 5’ long terminal repeat during oncogenesis. J Virol. 2007;81:5714–23. https://doi.org/10.1128/jvi.02511-06. e-pub ahead of print 2007/03/09
Inoue Y, Fuji S, Tanosaki R, Inamoto Y, Tanaka T, Ito A, et al. Prognostic importance of pretransplant disease status for posttransplant outcomes in patients with adult T cell leukemia/lymphoma. Bone Marrow Transpl. 2018;53:1105–15. https://doi.org/10.1038/s41409-018-0139-z. e-pub ahead of print 2018/03/11
Yamada K, Miyoshi H, Yoshida N, Shimono J, Sato K, Nakashima K, et al. Human T-cell lymphotropic virus HBZ and tax mRNA expression are associated with specific clinicopathological features in adult T-cell leukemia/lymphoma. Mod Pathol. 2021;34:314–26. https://doi.org/10.1038/s41379-020-00654-0. e-pub ahead of print 2020/09/26
Acknowledgements
We thank Dr. Linda Kingsbury for editorial comments and proofreading. This study was supported by the Ministry of Health Labour and Welfare (200300159A, 200622016B, 200925013B, and 201221027B to J-IY, IlC, YS, NU, JO, and MM), the Research Program on Emerging and Re-emerging Infectious Diseases (20fk0108088h0002 to J-IY and MM) from the Japan Agency for Medical Research and Development (AMED), and JSPS KAKENHI (19H03689 to MM and 20H03514 to J-IY). This study was also supported in part by the JSPS Core-to-Core Program A, Advanced Research Networks.
Author information
Authors and Affiliations
Contributions
KT performed experiments; KT, JY, and IC, collected and analyzed the data; IC, YS, NU, and JO organized and conducted the ATL-NST trials, and collected the samples; KT, JY, and MM designed the research and wrote the manuscript; and all authors approved the final version of manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Toyoda, K., Yasunaga, Ji., Choi, I. et al. The HTLV-1 proviral status is a potential prognostic biomarker for adult T-cell leukemia-lymphoma treated with allogeneic stem cell transplantation. Bone Marrow Transplant 56, 2027–2030 (2021). https://doi.org/10.1038/s41409-021-01311-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-021-01311-z